Enfortumab Vedotin & Pembrolizumab: New Hope for Muscle-Invasive Bladder Cancer

New data presented at the European Association of Urology (EAU) 2026 conference offer encouraging results for patients with muscle-invasive bladder cancer who are ineligible for cisplatin chemotherapy. The KEYNOTE-905/EV-303 study examines the use of neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab, a combination therapy, and its impact on surgical outcomes in this patient population. This research builds on growing evidence supporting the role of immunotherapy and antibody-drug conjugates in treating advanced bladder cancer, particularly for those who cannot tolerate standard cisplatin-based regimens.

Understanding Muscle-Invasive Bladder Cancer and Treatment Challenges

Muscle-invasive bladder cancer (MIBC) is an aggressive form of the disease where cancer cells have grown into the deeper muscle layers of the bladder. Treatment typically involves a combination of surgery to remove the bladder (cystectomy) and chemotherapy, often with cisplatin. However, a significant proportion of patients – estimated to be around 40-50% – are ineligible for cisplatin due to pre-existing kidney problems, hearing loss, or other health conditions. SurvivorNet explains that finding effective alternatives for these patients is a critical unmet demand.

KEYNOTE-905/EV-303: Study Design and Initial Findings

The KEYNOTE-905/EV-303 trial, as presented at EAU 2026 and reported by UroToday, is a neoadjuvant (before surgery) and adjuvant (after surgery) study. Participants with MIBC who were ineligible for cisplatin received both enfortumab vedotin and pembrolizumab. Enfortumab vedotin is an antibody-drug conjugate, meaning it delivers a chemotherapy drug directly to cancer cells, while pembrolizumab is an immunotherapy drug that helps the body’s immune system recognize and attack cancer. The study’s primary focus is on assessing surgical outcomes, including the rate of complete pathological response – meaning no cancer cells are found in the bladder after surgery.

While detailed results regarding the complete pathological response rate haven’t been fully released as of March 14, 2026, preliminary findings suggest a promising trend. The combination therapy appears to be well-tolerated, and the assessment of surgical specimens indicates a potential for improved outcomes compared to historical data with other neoadjuvant approaches in cisplatin-ineligible patients.

The Role of Enfortumab Vedotin and Pembrolizumab

Enfortumab vedotin has already demonstrated efficacy in treating advanced urothelial carcinoma (bladder cancer) that has spread to other parts of the body. Oncodaily reports on studies showing its effectiveness, particularly when combined with pembrolizumab. Pembrolizumab, a type of immune checkpoint inhibitor, works by blocking proteins that prevent the immune system from attacking cancer cells. Combining these two agents may offer a synergistic effect, enhancing the body’s ability to fight bladder cancer.

Understanding Complete Pathological Response

Complete pathological response is a significant endpoint in bladder cancer trials. Achieving this response is associated with improved long-term survival rates. However, it’s vital to note that a complete pathological response does not guarantee that the cancer will never return, but it significantly reduces the risk of recurrence.

What This Means for Patients

The KEYNOTE-905/EV-303 study offers a potential new treatment option for patients with muscle-invasive bladder cancer who are unable to receive cisplatin chemotherapy. This is a particularly important development, as these patients historically have had limited treatment choices and often face a poorer prognosis. The combination of enfortumab vedotin and pembrolizumab may provide a more effective and tolerable alternative, potentially leading to better surgical outcomes and improved long-term survival.

It’s crucial to remember that this research is ongoing, and further follow-up is needed to confirm these initial findings. The long-term effects of this treatment regimen, including potential side effects and the durability of the response, are still being evaluated.

Next Steps and Ongoing Research

Researchers will continue to follow patients enrolled in the KEYNOTE-905/EV-303 study to assess long-term outcomes, including recurrence rates and overall survival. Further analysis will also focus on identifying biomarkers that may predict which patients are most likely to benefit from this combination therapy. The data from this trial will likely inform future clinical guidelines and treatment recommendations for muscle-invasive bladder cancer in cisplatin-ineligible patients. Additional studies are also underway to explore the potential of enfortumab vedotin and pembrolizumab in other bladder cancer settings, including earlier stages of the disease and in combination with other therapies.

Patients with muscle-invasive bladder cancer should discuss their treatment options with a qualified oncologist to determine the best course of action based on their individual circumstances. Staying informed about the latest research developments and participating in clinical trials, when appropriate, can also empower patients to make informed decisions about their care.